VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the management team will discuss VBI-2601, the Company’s vaccine immunotherapeutic candidate in development for a functional cure for hepatitis B (HBV) infection, in a fireside chat at the H.C. Wainwright Hepatitis B Virus (HBV) M
October 15, 2020
· 4 min read